OKYO Pharma (OKYO) Debt Ratio (2023 - 2025)

OKYO Pharma (OKYO) reported Debt Ratio of 0.04 for Q3 2025, up 6159.93% year-over-year from 0.0 in Q3 2024, and down 82.88% quarter-over-quarter from 0.23 in Q1 2025.

OKYO Pharma (OKYO) Debt Ratio (2023 - 2025) Analysis & Trends

OKYO Pharma (OKYO) has 3 years of Debt Ratio data on file, last reported at 0.04 in Q3 2025.

  • Debt Ratio for Q3 2025 came in at 0.04, up 6159.93% year-over-year; the trailing twelve-month figure through Sep 2025 was 0.04 (up 6159.93% YoY), and the FY2025 annual result was 0.23, changed 0.41% from the prior year.
  • Debt Ratio declined to 0.04 in Q3 2025 per OKYO's latest filing, from 0.23 in the prior quarter.
  • Over five years, Debt Ratio peaked at 0.23 in Q1 2025 and troughed at 0.0 in Q3 2024.
  • A 3-year average of 0.15 and a median of 0.22 in 2023 frame the typical range for Debt Ratio.
  • The sharpest annual moves came in 2024 and 2025: Debt Ratio plunged 99.71% in 2024, then surged 6159.93% in 2025.
  • A 3-year view of Debt Ratio shows it stood at 0.22 in 2023, then sank by 99.71% to 0.0 in 2024, then jumped by 6159.93% to 0.04 in 2025.
  • Business Quant data shows OKYO's Debt Ratio at 0.04 in Q3 2025, 0.23 in Q1 2025, and 0.0 in Q3 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Alterity Therapeutics 723,416.35 Bn 723,416.32 Bn - -
2 Belite Bio 57,340.00 Bn 57,340.00 Bn - -
3 Quantum Biopharma 19,125.08 Bn 19,125.08 Bn - -
4 Legend Biotech 3,262.00 Bn 3,261.71 Bn 242.10 Mn 0.18
5 Akari Therapeutics 1,789.67 Bn 1,789.67 Bn - -
6 Evaxion A 1,480.39 Bn 1,480.37 Bn - -
7 Psyence Biomedical 241.78 Bn 241.78 Bn - -
8 Vertex Pharmaceuticals 113.54 Bn 106.29 Bn 2.59 Bn -
9 Abivax 94.26 Bn 94.26 Bn - -
10 OKYO Pharma 244.98 Mn 240.76 Mn - 0.04

Historic Data

Download Data
DateValue
Sep 30, 2025 0.04
Mar 31, 2025 0.23
Sep 30, 2024 0.00
Mar 31, 2024 0.23
Sep 30, 2023 0.22